Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer

CD8+ T cells in the central nervous system of mice with herpes simplex infection are highly activated and express high levels of CCR5 and CXCR3

(2021) Liza Lind et al.   JOURNAL OF NEUROVIROLOGY

Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma

(2020) TEIJI KUZUYA et al.   ANTICANCER RESEARCH

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

(2020) Vicky Makker et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

(2020) Akihito Kawazoe et al.   LANCET ONCOLOGY

Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

(2020) Jianzhen Lin et al.   Hepatobiliary Surgery and Nutrition

CAR-NK cells: A promising cellular immunotherapy for cancer

(2020) Guozhu Xie et al.   EBioMedicine

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

(2020) Kayoko Kasuya et al.   INTERNAL MEDICINE

CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models

(2019) Huizhong Li et al.   JOURNAL OF IMMUNOTHERAPY

Lenvatinib for the treatment of renal cell carcinoma

(2018) Giandomenico Roviello et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model

(2018) Takayuki Kimura et al.   CANCER SCIENCE

Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens

(2017) Jinjing Xu et al.   Expert Review of Anticancer Therapy

Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer

(2017) Nobuhiko Arai et al.   World Neurosurgery

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

(2016) C. H. J. Lamers et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma

(2016) Robert J Motzer et al.   LANCET ONCOLOGY

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

(2015) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

(2013) Kiyoshi Okamoto et al.   CANCER LETTERS

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer

(2013) D. Alizadeh et al.   CANCER RESEARCH

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

(2011) K. Yamada et al.   CLINICAL CANCER RESEARCH